Tenaya Therapeutics, Inc. (TNYA) News
Filter TNYA News Items
TNYA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TNYA News From Around the Web
Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 35th Annual Piper Sandler Healthcare Conference taking place in New York, NY. Details of participation are as follows: Fireside ChatDate: Novem |
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateCommenced Patient Dosing in MyPeak-1TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 TN-401 for PKP2-Associated ARVC Received FDA Clearance to Begin First-in-Human Clinical Testing and Fast Track Designation SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechn |
Institutional investors have a lot riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) with 38% ownershipKey Insights Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their... |
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyPKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated Robust Reduction of Ventricular Arrhythmias and Extended Survival in Knockout Models of Disease After a Single Dose SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and |
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific MeetingTN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and Highlights Differentiated Mechanism of Action SOUTH SAN FRANCISCO, Calif. and CLEVELAND, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to di |
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyTN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be Assessed in Humans; Adds Working MYBPC3 Gene to Heart Cells to Address Underlying Cause of DiseaseSOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the first patient has been do |
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac RegenerationNovel AAV-Based Approach Regenerated Myocardial Cells and Demonstrated Durable Benefit to Heart Function in Rodent Model of Chronic Cardiac Ischemic InjurySOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the Octobe |
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical ConferencesTN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study Data and Phase 1b Clinical Trial Design to be Featured at Hypertrophic Cardiomyopathy Medical Society Scientific Sessions SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, devel |
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 21st Annual Morgan Stanley Global Healthcare Conference taking place in New York City. Details of participation are as follows: Fireside ChatDa |